Jefferies Group’s VRTX Holdings & Trades

First Buy
Q1 2016
Duration Held
39 Quarters
Largest Add
Q1 2024
+38,814 Shares
Current Position
16,000 Shares
$6.27 M Value

Jefferies Group's VRTX Position Overview

Jefferies Group (via Jefferies Financial Group Inc.) currently holds 16,000 shares of Vertex Pharmaceuticals Incorporated (VRTX) worth $6.27 M, representing 0.03% of the portfolio. First purchased in 2016-Q1, this long-term strategic position has been held for 39 quarters.

Based on 13F filings, Jefferies Group has maintained a strategic position in VRTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2024, adding 38,814 shares. Largest reduction occurred in Q3 2024, reducing 27,632 shares.

Analysis based on 13F filings available since 2013 Q2

Jefferies Group's Vertex Pharmaceuticals Incorporated (VRTX) Holding Value Over Time

Track share changes against reported price movement

Quarterly Vertex Pharmaceuticals Incorporated (VRTX) Trades by Jefferies Group

Period Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2016 +3,300 New Buy 3,300 $79.39
Q2 2016 -3,300 Sold Out 3,300 $0.00
Q4 2022 +7,488 New Buy 7,488 $288.78
Q1 2023 +3,636 Add 48.56% 11,124 $315.07
Q2 2023 -191 Reduce 1.72% 10,933 $351.91
Q3 2023 -10,632 Reduce 97.25% 301 $347.74
Q4 2023 +17,707 Add 5882.72% 18,008 $406.89
Q1 2024 +38,814 Add 215.54% 56,822 $418.01
Q2 2024 +3,453 Add 6.08% 60,275 $468.72
Q3 2024 -27,632 Reduce 45.84% 32,643 $465.08
Q4 2024 -18,659 Reduce 57.16% 13,984 $402.70
Q1 2025 +5,500 Add 39.33% 19,484 $484.82
Q2 2025 +15,131 Add 77.66% 34,615 $445.20
Q3 2025 -18,615 Reduce 53.78% 16,000 $391.64

Jefferies Group's Vertex Pharmaceuticals Incorporated Investment FAQs

Jefferies Group first purchased Vertex Pharmaceuticals Incorporated (VRTX) in Q1 2016, acquiring 3,300 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Jefferies Group has held Vertex Pharmaceuticals Incorporated (VRTX) for 39 quarters since Q1 2016. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Jefferies Group's largest addition to Vertex Pharmaceuticals Incorporated (VRTX) was in Q1 2024, adding 56,822 shares worth $23.75 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

According to the latest 13F filing for Q3 2025, Jefferies Group's firm, Jefferies Financial Group Inc., owns 16,000 shares of Vertex Pharmaceuticals Incorporated (VRTX), valued at approximately $6.27 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

As of the Q3 2025 filing, Vertex Pharmaceuticals Incorporated (VRTX) represents approximately 0.03% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Jefferies Group's peak holding in Vertex Pharmaceuticals Incorporated (VRTX) was 60,275 shares, as reported at the end of Q2 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.